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B
rain metastases occur in up to 30% of patients with systemic cancers, 1 and seizures are a common sequela of brain metastases. 2 While antiepileptic drug (AED) use after seizure occurrence is well-established in patients with brain metastases, 3 the efficacy of prophylactic AEDs for patients with brain metastases who do not undergo surgery remains an unresolved issue. The objective of this guideline is to address the role of AED prophylaxis in patients with brain metastases without prior seizures in the (1) nonsurgical setting and (2) postoperative setting.
METHODS
The PubMed, Embase, and Cochrane CENTRAL online databases was searched from January 1, 1980, through December 31, 2015, using query terms described in the main text to identify pertinent studies on prophylactic AED use in brain metastasis patients without prior history of seizures. A total of ABBREVIATIONS: AED, antiepileptic drug; PHT, phenytoin; VAL, valproate 8167 citations were identified and reviewed; 8127 studies were excluded during title/abstract review. The remaining 40 studies underwent full-text review, and 35 studies were excluded due to limited metastasesspecific data, a lack of information regarding use of AEDs, lack of information on surgical intervention, lack of a comparison cohort without AED prophylaxis, or other predefined exclusion criteria. Five studies met our inclusion criteria.
RESULTS

Seizure Prophylaxis in Patients with Brain Metastases who did not Undergo Surgery
Two studies met inclusion criteria and provided information pertaining to this issue. Forsyth et al 4 randomized 100 brain tumor patients with no prior history of seizure to receive either (1) AED for 3 mo, in the form of phenytoin (PHT) or phenobarbital, or (2) no AED. Sixty of the 100 (60%) study patients suffered from brain metastases. Of the patients with brain metastases, 26 were treated with AEDs, and 34 were not. The primary study endpoint was seizure occurrence (up to 3 mo). The overall study showed that seizures occurred in 26% of patients treated with AEDs and 15% in the non-AED group (P = .98). Glantz et al 5 randomized 74 brain tumor patients with no prior history of seizures to receive either (1) valproate (VAL), or (2) placebo pill for the study duration. Fifty-nine of these patients (80%) suffered from brain metastases. The primary study endpoints were as follows: new onset seizure or death within 12 mo of enrollment. The overall study showed that seizures occurred in 35% of patients treated with VAL and 24% in the placebo group (P = .3).
Neither study provided compelling data to support recommendation for prophylactic AED for brain metastasis patients without prior history of seizures.
Seizure Prophylaxis in Patients with Brain Metastases in the Postoperative Setting
Three studies met inclusion criteria and provided information pertaining to this issue.
Ansari et al 6 retrospectively reviewed AED use and seizure frequency in 202 patients with no previous seizure history who underwent craniotomies for intra-axial brain tumors. Eighty-six of the 202 patients (43%) in this study suffered from brain metastases. The overall study showed that 22.8% of patients had postoperative seizures (median follow-up 321 d). No significant difference was found in patients who received prophylactic AEDs when compared to patients not on prophylactic AEDs (P = .2867).
Wu et al 7 randomized 123 brain tumor patients with no prior seizure history to PHT or no AED in the postoperative setting for a 7-d duration. Seventy-seven of the 123 patients (62%) in this study suffered from brain metastases (80% of the remaining 46 patients suffered from high grade glioma). The primary study endpoint was seizure occurrence (<30 d), and a secondary endpoint was the occurrence of adverse reactions to PHT. The study results showed that 24% of the PHT group suffered seizures within 30 d of surgery while 18% of the no AED cohort suffered seizure within 30 d (P = .51).
Franceschetti et al 8 randomized 63 brain tumor patients without prior history of seizures to AEDs (phenobarbital or PHT, n = 41) or no AED (n = 22) in the postoperative setting. AEDs were maintained for the duration of the study. Thirteen of the 63 (21%) patients in this study suffered from brain metastases. The end points assessed were early (<1 wk) and late (>1 wk) postoperative seizures. The overall study results showed that early postoperative seizures occurred in 7% of the AED cohort and 18% of the non-AED cohort (P = .23). Late postoperative seizures occurred in 12% of the AED cohort and 21% of the non-AED cohort (P = .64). Seizure < 1 wk was not associated with seizure >1 wk.
These studies do not provide compelling data in support recommendation for prophylactic AED for brain metastasis patients without prior history of seizures in the post-operative setting.
CONCLUSION
The available data support level 3 recommendation against the routine use of prophylactic AEDs in brain metastasis patients without prior history of seizure.
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